Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research (DENEM)

28 de agosto de 2026 atualizado por: Liverpool School of Tropical Medicine

Dengue Evaluation of Multi-State Models (DENEM Study): A Prospective Observational Study of Patients Hospitalised With Dengue Vascular Leak in Nha Trang, Vietnam, to Develop Novel Statistical Methodology

The goal of this observational study is to investigate the natural history of dengue in hospitalised patients in Vietnam, to better understand the disease process, and utilise the data to improve future clinical trials. The main questions it aims to answer are:

In participants hospitalised with dengue in Vietnam:

  1. How does dengue illness change over time, particularly the development and recovery of vascular leak (where blood vessels leak)?
  2. Can a new statistical approaches describe dengue illness accurately and be suitable for use in future clinical trials?
  3. Which blood biomarkers are associated with worsening or improving dengue illness, and what do they tell us about how severe dengue develops? Could these blood biomarkers act as reliable indicators of disease severity and recovery, making them useful outcome measures in future dengue treatment trials?
  4. How accurately do simplified diagnostic tests identify dengue compared with laboratory reference methods, and are they suitable for use in research and clinical settings in low- and middle-income countries?

Participants will be observed without any intervention throughout their hospitalisation. Participants will be be asked to provide informed consent for:

  • Recording of their routine clinical data
  • Regular blood tests
  • Regular ultrasound scans
  • A follow up appointment.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

Dengue is a life-threatening infection caused by a virus, spread between humans by the bite of mosquitoes. It is present throughout the tropics, including in Vietnam, where cases have dramatically increased in recent years. Dengue causes severe illness predominantly through vascular leak, where patients' blood vessels break down, becoming leaky, leading to fluid from the vessels moving into tissues and organs such as the lungs.

However, it is still not fully understand how the virus causes vascular leak, or in which patients it is most likely to occur in. There are no licensed treatments for vascular leak. This is because the mechanism of vascular leak is incompletely understood, making therapeutic targeting difficult. Additionally, when drugs are trialled, many trials have been poorly designed and not included enough patients.

To answer our research questions, the investigators will recruit 142 patients admitted to hospital with dengue in Nha Trang, Vietnam who have dengue vascular leak. If they are happy to enter the study, data will be recorded that is already being collected as part of their hospital admission; this will include clinical data (such as blood pressure, pulse and treatments given) and the results of their blood tests. Investigators will also run tests beyond what they would normally have in hospital; this will include the results of regular ultrasound scans and biomarker blood tests (small molecules that can be detected in their blood in response to stress and vascular leak). Most patients have blood tests daily in hospital, and clinicians will aim to take the extra tubes of blood required at the same time, to minimise the number of extra procedures requested from participants.

Investigators will put this data it into a statistical model of dengue vascular leak they have been developing, called a multi-state model. These models have previously been used in other areas of medicine, but this would be their first application in dengue and infectious diseases research. Multi-state models aim to track how patients move through different stages of illness over time. Models such as this make better use of all the information collected during a patient's illness. Rather than only looking at a single outcome, such as whether a patient had recovered by a certain day, or how long recovery took, they track how patients move through different stages of dengue over time and how long they spend in each stage. This may give a more complete picture of how treatments affect the course of illness. If successful, it could improve how future dengue clinical trials are designed, helping researchers detect whether new treatments work more quickly and with fewer volunteers.

Investigators will also use data and samples collected from this study to explore why vascular leak occurs and evaluate new ways of diagnosing dengue, particularly in low-resource settings. To achieve this, investigators will need to compare patients who have dengue to people who have not got dengue, looking for differences. As such 93 people who do not have dengue (called "control" participants) will be recruited. Some will have a fever from another cause, and others will be healthy volunteers. Comparing these control populations with patients who have dengue helps us understand which findings are specific to dengue and how accurate new dengue tests are. People in these groups will only have a single small blood sample taken and will not receive any treatment or need follow-up visits.

Overall, this study aims to support the development of better treatments and more efficient clinical trials for dengue.

Tipo de estudo

Observacional

Inscrição (Estimado)

235

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Nha Trang, Vietnã
        • Nagasaki University Vietnam Research Station, Nha Trang
        • Contato:
        • Investigador principal:
          • Lay Myint Yoshida, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients presenting to Khánh Hòa Hospital of Tropical Diseases, Nha Trang, Vietnam.

Descrição

Inclusion Criteria (hospitalised cohort):

  • Meet the 2009 WHO criteria for dengue with warning signs or severe dengue AND
  • Are being admitted as an inpatient AND
  • Have documented standard-of-care laboratory confirmation of dengue (defined as either positive by molecular assay (e.g. reverse transcription polymerase chain reaction) OR positive by antigen testing (non-structural protein-1) OR positive Immunoglobulin M (IgM) combined with clinical diagnosis of dengue by attending physician. AND
  • Were born in Vietnam (only for platelet phenomics substudy)

Inclusion Criteria (diagnostic control cohort):

  • Have a documented fever at assessment AND
  • Have a documented negative standard-of-care dengue test, with no clinical diagnosis of dengue AND
  • Were born in Vietnam (only for platelet phenomics substudy)

Inclusion Criteria (platelet control cohort):

  • Vietnamese-born adults ≥16 years of age with no history of febrile illness in the preceding 14 days.

Exclusion Criteria:

  • Receiving an experimental dengue treatment during their illness.
  • Inability to provide written, informed consent AND no legal guardian able to provide written, informed consent in the event of incapacity.
  • Clinician-determined unsuitability for recruitment.

Exclusion Criteria (platelet substudy only):

  • Any non-steroidal anti-inflammatory, antiplatelet or anticoagulant medication received in preceding 7 days.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Hospitalised Cohort
Patients hospitalised with dengue with warning signs or severe dengue
Diagnostic Control Cohort
Patients with non-dengue febrile illness
Platelet Control Cohort
Healthy Vietnamese volunteers

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Degree of vascular leak
Prazo: From enrollment until day 10 of illness, or discharge
Presence and severity of vascular leak (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - composite of change of haematocrit from baseline, presence of ascites/pleural effusion by point of care ultrasound and presence of respiratory/cardiovascular compromise.
From enrollment until day 10 of illness, or discharge

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Multi-state model evaluation - precision
Prazo: Assessed at 3 days and 5 days post admission
Confidence in model parameters: 95% confidence interval width around 3- and 5-day probabilities of all state transition pairs (probability with 95% confidence interval)
Assessed at 3 days and 5 days post admission
Multi-state model evaluation: model fit
Prazo: From enrollment until day 10 of illness or discharge
Goodness of fit of model compared to observed data, as assessed by Akaike information criteria (AIC) values, Bayesian information criteria (BIC) values and Likelihood-ratio test (p-value)
From enrollment until day 10 of illness or discharge
Viral dynamics
Prazo: From enrollment until day 10 of illness, or discharge
Dengue viral load by reverse-transcriptase polymerase chain reaction (copies per microlitre)
From enrollment until day 10 of illness, or discharge
Degree of thrombocytopenia
Prazo: From enrollment until day 10 of illness or discharge
Presence and severirty of thrombocytopenia (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - measured by platelet count (10^9/L)
From enrollment until day 10 of illness or discharge
Degree of bleeding
Prazo: From enrollment until day 10 of illness or discharge
Presence and severirty of bleeding (none, moderate, severe) per Tomashek et al. 2018 consensus definitions - composite score measured by presence/absence of clinical bleeding, requirement for local intervention, cardiovascular compromise, requirement for blood transfusion.
From enrollment until day 10 of illness or discharge
Modified sequenetial organ failure score (mSOFA)
Prazo: From enrollment until day 10 of illness or discharge
mSOFA score composite score (0-24) with 6 systems assessed, each component contributing 0-4 points to the overal score. Systems assessed: respiratory system (peripheral saturations of oxygen/fraction inspired oxygen, mmHg), Coagulation (platelet count / microlitre), Liver function (Bilirubin, mg/dl), Cardiovascular system (mean arterial pressure / pulse pressure, mmHg), Central nervous system (glasgow coma score), renal function (creatinin, mg/dL or urine output, mL/day)
From enrollment until day 10 of illness or discharge
Volume of Intravenous Fluid Received in 24 hours
Prazo: From enrollment until day 10 of illness or discharge
Fluid type and volume (mL)
From enrollment until day 10 of illness or discharge
Dengue Clinical Severity
Prazo: From enrollment until day 10 of illness or discharge
Dengue clinical severity classification per WHO 2009 criteria (dengue without warning signs, dengue with warning signs, severe dengue)
From enrollment until day 10 of illness or discharge
Concentration of a panel of plasma biomarkers of endothelial dysfunction, inflammation and platelet dysfunction.
Prazo: From enrollment until day 10 of illness, or discharge
Longitudinal measurement of biomarkers such as Syndecan-1, Angiopoietin 1/2, VCAM-1, CRP, Ferritin, platelet function assay, platelet-leucocyte aggregate assay, platelet receptor panel
From enrollment until day 10 of illness, or discharge
Performance of plasma biomarkers of dengue vascular leak as robust secondary endpoints in future dengue interventional trials.
Prazo: From enrollment until day 10 of illness or discharge
Correlation of biomarker values with clinical and model outcomes
From enrollment until day 10 of illness or discharge
Performance of dengue diagnostic platforms, for use in participant screening in low- and middle-income countries.
Prazo: At enrollment
Diagnostic accuracy of novel LAMP assay compared to reference standard and RDT: sensitivity, specificity and predictive values of diagnostic platforms against RT-PCR as reference and RDTs as standard of care.
At enrollment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de novembro de 2026

Conclusão Primária (Estimado)

1 de abril de 2028

Conclusão do estudo (Estimado)

1 de abril de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

5 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de agosto de 2026

Primeira postagem (Real)

2 de setembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Anonymised study results will be made publicly available through scientific publications and, where appropriate, data repositories. Requests from bona fide researchers for access to de-identified participant-level data will be considered on a case-by-case basis, subject to applicable ethical approvals, participant consent, and local and institutional policies.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • ANALYTIC_CODE

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever